BASEL, Switzerland--(BUSINESS WIRE)--Polyneuron Pharmaceuticals AG, a clinical stage developer of a new class of antigen-specific polymers for the treatment of patients with serious autoimmune diseases, today announced the appointment of Aled Williams as Chief Business Officer. Mr Williams joins Polyneuron with more than 25 years’ of leadership experience in the pharmaceutical industry, with a recent focus on developing and commercialising rare disease therapeutics.
BASEL, Switzerland--(BUSINESS WIRE)--Polyneuron Pharmaceuticals AG, a clinical stage developer of a new class of biodegradable glycopolymers for the treatment of autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to PN?1007 (PPSGG) in the treatment of anti-MAG neuropathy, a disabling, chronic disorder of the peripheral nervous system. Orphan designation is granted to advance the development of safe and effective therapies for the treatment of rare diseases or conditions affecting fewer than 200,000 individuals in the U.S. Under the Orphan Drug Act, the FDA may provide grant funding toward clinical trial costs, tax credits, FDA user-fee benefits, and seven years of market exclusivity following marketing approval. PN?1007 received orphan drug designation from the European Medicines Agency in July 2017.